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1 Drug description 
Generic/Brand name:  
Bendamustine Hydrochloride / Ribomustin® (Germany, Switzerland)  
Bendamustine / Levact® (Bendamustine is currently undergoing regulatory 
review in 12 countries across Europe [1]) 
Bendamustine Hydrochloride / Treanda® (USA) 
Developer/Company:  
Bendamustine (RIBOMUSTIN®) is licensed from Astellas Deutschland 
GmbH and is marketed in Germany and Switzerland by the Mundipharma 
independent associated companies (e.g. Mundipharma International). In the 
United States, bendamustine (TREANDA®) is marketed by Cephalon Inc. 
SymBio Pharmaceuticals Ltd holds exclusive rights for developing and mar-
keting bendamustine in Japan (sublicensed to Eisai Co Ltd) and selected 
Asian countries. 
Description:  
Bendamustine, a chemotherapeutic agent for cancer therapy, is a bifunc-
tional mechlorethamine derivative (nitrogen mustard group which contains 
a purine-like benzimidazole ring). The nitrogen mustard group is structur-
ally similar to cyclophosphamide and chlorambucil and gives the drug its 
alkylating properties while the benzimidazole ring may be responsible for its 
antimetabolite properties. The precise cytotoxic mechanism of action re-
mains unclear [2]. 
Bendamustine causes only partial cross-resistance to other alkylating agents 
and anthracyclines and this has been cited as one advantage over other che-
motherapeutic agents [3]. 
Bendamustine Hydrochloride is available in single-use vials containing ei-
ther 25 mg or 100 mg of bendamustine hydrochloride as white to off-white 
lyophilized powder. After reconstitution with sterile water it should be ad-
ministered by intravenous infusion over 30 (to 60) minutes. 
The recommended dosage of bendamustine in CLL is 70-100 mg/m2 in 0.9% 
NaCl solution (up to 500ml) on Days 1 and 2 of a 28 day cycle for up to 6 cy-
cles (dose depends on use as single agent or in combination) [4, 5].  
There are different treatment regimes for its use in indolent non-Hodgkin's 
lymphomas (NHL). The recommended dosage as single agent is 120 mg/m2 
infused intravenously over 60 minutes on Days 1 and 2 of a 21 day cycle for 
up to 8 cycles, when used in combination with vincristine and prednisone 
the dosage is 60 mg/m2 infused intravenously on Days 1 to 5 [4, 5]. 
The recommended dosage of bendamustine in multiple myeloma is 120-150 
mg/m2 in 0.9% NaCl solution (up to 500ml) infused intravenously on Days 1 
and 2 of a 28 day cycle [5]. 
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2 Indication 
Bendamustine is indicated for 
- indolent non-Hodgkin's lymphomas (NHL) 
- chronic lymphocytic leukaemia  (CLL) 
- advanced multiple myeloma (MM) stage II (with progression) and 
stage III  
3 Current regulatory status 
Bendamustine was first synthesized in the early 1960s at the Institute for 
Microbiology and Experimental Therapy in Jena (Germany). It was widely 
used but never studied systematically in patients until the 1990s. Then 
German investigators demonstrated its clinical activity in a number of ma-
lignancies and bendamustine received its first marketing approval in Ger-
many in 2005, for use as single agent or in combination-chemotherapy re-
gimes for indolent non-Hodgkin's lymphomas (NHL), multiple myeloma 
(MM) and chronic lymphocytic leukaemia (CLL). Trials conducted outside 
of Germany led to the approval of bendamustine (TREANDA®) by the FDA 
in 2008 [2, 6] for the following indications: 
- Chronic lymphocytic leukaemia (CLL). Efficacy relative to first 
line therapies other than chlorambucil has not been established 
- Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has pro-
gressed during or within six months of treatment with rituximab or 
a rituximab containing regimen. 
In addition, bendamustine has been approved in Switzerland  
(RIBOMUSTIN®) for CLL since March 2009 [7]. 
Moreover, Astellas Pharma GmbH submitted Levact (bendamustine hydro-
chloride) to the German medicines regulatory agency for a decentralised 
procedure. This is a procedure where one Member State (the ‘reference 
Member State’, in this instance Germany) assesses a medicine with a view to 
granting a marketing authorisation that will be valid in that country as well 
as in other Member States (the ‘concerned Member States’, in this instance 
Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, 
Poland, Spain and the United Kingdom). However, the Member States were 
not able to reach an agreement and the German medicines regulatory agency 
referred the matter to the CHMP for arbitration on 2 October 2009 [8]. In 
March 2010 the CHMP concluded that marketing authorisation can be 
granted in the following indications: 
- Chronic lymphocytic leukaemia in patients for whom treatment 
with fludarabine is not appropriate 
- Non-Hodgkin’s lymphoma in patients who have had a relapse fol-
lowing treatment containing rituximab 
- Multiple myeloma in combination with prednisone for patients 
older than 65 years who are not eligible for autologous stem cell 
indolent NHL, CLL and 
multiple myeloma 
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USA since 2008 
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transplantation and cannot be treated with thalidomide or borte-
zomib 
Following the CHMP conclusion, a subsequent European Commission deci-
sion, and the granting of national licences, the first launches of benda-
mustine (LEVACT®) in the European Union are anticipated in mid-2010 in 
Austria, Denmark, Finland and the UK [9]. 
4 Burden of disease 
Indolent Non-Hodgkin’s lymphomas (NHL) 
Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lym-
phoproliferative disorders originating in B-lymphocytes, T-lymphocytes or 
natural killer lymphocytes (white blood cells). About 90% of NHLs are B-
cell lymphomas and about 10% of NHL cases are T-cell and NK lympho-
mas. There are many different types of non-Hodgkin’s lymphomas. NHL is 
much less predictable than Hodgkin lymphoma and has a far greater predi-
lection to disseminate to extranodal sites. The prognosis depends on the his-
tological type, stage, and treatment.  
NHL can be divided into two prognostic groups: the indolent (slow-growing) 
lymphomas and the aggressive (fast-growing) lymphomas. Indolent NHL 
types have a relatively good prognosis with a median survival of 10 years, but 
they are usually not curable in advanced clinical stages. Early stage (stage I 
and stage II) indolent NHL can be effectively treated with radiation therapy 
alone. Most of the indolent types are nodular (or follicular) in morphology. 
The aggressive type of NHL has a shorter natural history, but a significant 
number of these patients can be cured with intensive combination chemo-
therapy regimens. In general, with modern treatment of patients with NHL, 
overall survival at 5 years is approximately 50% to 60%. Of patients with ag-
gressive NHL, 30% to 60% can be cured. The vast majority of relapses occur 
in the first 2 years after therapy. The risk of late relapse is higher in patients 
with a divergent histology of both indolent and aggressive disease [10].   
Since 2001 the World Health Organization (WHO) classification is the in-
ternationally accepted classification of NHL, which is a refinement of the 
REAL classification, the Revised European-American Classification of 
Lymphoid neoplasm. The stages of NHL follow the Ann-Arbor-Staging sys-
tem. The Ann Arbor staging system with Cotswold modification, originally 
developed for Hodgkin lymphoma, has been adapted for staging NHL. This 
staging system focuses on the number of tumour sites -nodal and extranodal- 
location, and the presence or absence of systemic ("B") symptoms: 
 Stage I refers to NHL involving a single lymph node region (stage 
I) or a single extralymphatic organ or site (stage IE).  
 Stage II refers to two or more involved lymph node regions on the 
same side of the diaphragm (stage II) or with localized involvement 
of an extralymphatic organ or site (stage IIE).  
 Stage III refers to lymph node involvement on both sides of the 
diaphragm (stage III), or with localized involvement of an extra-
lymphatic organ or site (stage IIIE) or spleen (stage IIIS), or both 
(stage IIIES).  
heterogeneous group of 
disorders 
two prognostic groups: 
indolent NHL, 
aggressive NHL 
Ann Arbor Staging 
system 
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 Stage IV refers to the presence of diffuse or disseminated involve-
ment of one or more extralymphatic organs (eg, liver, bone marrow, 
lung), with or without associated lymph node involvement.  
 The presence or absence of systemic symptoms should be noted 
with each stage designation. (A = asymptomatic. B = presence of 
fever (>38 degrees C), sweats, or weight loss >10 percent of body 
weight over six months. 
Since NHLs most frequently disseminate haematogenously, this staging sys-
tem has proven to be much less useful than for Hodgkin lymphoma, which 
disseminates principally by contiguous lymphatic extension. It is generally 
accepted that there is little therapeutic benefit in distinguishing between 
stages III and IV disease in NHL, since treatment options are nearly identi-
cal. Thus, staging is undertaken in NHLs to identify the small numbers of 
patients with "early stage disease" who can be treated with local therapy or 
combined modality treatment, and to stratify within histological subtypes in 
order to determine prognosis and assess the impact of treatment [11]. 
According to Statistik Austria 514 people died of NHL disease and 1057 new 
cases were diagnosed in 2007 in Austria. Thus, in 2007 the incidence of NHL 
was 7.6 per 100,000 (9.5 for men and 6.1 for women) [12].  
Multiple studies have demonstrated that prognosis is far more dependent 
upon histopathology, being only secondarily influenced by clinical parame-
ters including age, presence of extranodal disease, performance status, and 
stage (I/II versus III/IV). Since stage usually depends only upon the location 
and number of disease sites, it is not a true measure of tumour burden, 
which is clearly an important prognostic determinant in non-Hodgkin lym-
phoma, and may also affect the overall treatment program employed [11].  
Chronic Lymphocytic Leukaemia (CLL) 
Chronic lymphocytic leukaemia (CLL) is one of the chronic lymphoprolif-
erative disorders (lymphoid neoplasm). It is characterized by a progressive 
accumulation of functionally incompetent lymphocytes. CLL is considered 
to be identical (i.e., one disease at different stages) to the mature (periph-
eral) B-cell neoplasm small lymphocytic lymphoma (SLL), one of the indo-
lent non-Hodgkin lymphomas.  
CLL is the most common leukaemia in Western countries. The disorder is 
more common in men with a male to female ratio of approximately 1.7:1.  
In Austria the overall incidence of all forms of leukaemia was 7.6 per 
100,000 and the overall death rate of all forms of leukaemia was 4.6 per 
100,000 in 2007. Within men, the death rate was 6.0 per 100,000 and within 
women it was 3.6 per 100,000 in 2007 [13].  
CLL is considered to be mainly a disease of the elderly, with a median age at 
diagnosis of 70 years; however, it is not unusual to make this diagnosis in 
younger individuals from 30 to 39 years of age. The incidence increases rap-
idly with increasing age.  
Patients with CLL have a wide range of symptoms and physical and labora-
tory abnormalities at the time of diagnosis. Most patients consult a physi-
cian because they have noted painless swelling of lymph nodes. Approxi-
mately 25 percent of patients feel entirely well with no symptoms when a 
routine blood count reveals an absolute lymphocytosis, leading to a diagno-
sis of CLL [14]. 
incidence of 7.6 per 
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The natural history of CLL is extremely variable, with survival times from 
initial diagnosis that range from 2 to 20 years, and a median survival of ap-
proximately 10 years. Although patients with early stage disease have a 
greater than 10 year life expectancy, patients with more advanced disease 
have a median survival of 18 months to 3 years and those who have fludara-
bine refractory disease have a median survival of less than one year. Ad-
vances in the therapy for CLL, particularly "chemoimmunotherapy" regi-
mens combining cytotoxic agents such as alkylating agents and purine nu-
cleoside analogs with monoclonal antibodies such as rituximab, have im-
proved initial overall response (OR) rates, complete response (CR) rates and 
progression free survival (PFS). Despite these advances, CLL remains in-
curable with standard therapies [15]. 
There are two classification systems for the clinical staging of CLL, the Rai 
Classification and the Binet staging system. The Rai classification distin-
guishes low (formerly Rai stage 0), intermediate (formerly Rai stage I or II) 
and high (formerly Rai stage IV and V) risk disease, whereas the Binet stag-
ing is subdivided into stage A, B and C [16]. 
Multiple Myeloma 
Multiple myeloma (MM, plasmacytoma), one of the mature B-cell lymphoid 
neoplasm, is characterized by the accumulation of malignant plasma cells in 
the bone marrow compartment, increased production of a monoclonal im-
munoglobulin (Ig), and bone destruction. MM is an incurable disease and 
the cause of multiple myeloma is unknown.  MM is a disease of older adults. 
The median age at diagnosis is 66 years; only 10 and 2 percent of patients 
are younger than 50 and 40 years, respectively [17].  
MM accounts for approximately 1 percent of all cancers and slightly more 
than 10 percent of hematologic malignancies in Austria. The incidence of 
MM was about 2.5 per 100,000 (2.8 for men and 2.1 for women) in 2007 in 
Austria. In absolute numbers 180 men and 198 women were diagnosed with 
plasmacytoma in Austria in 2007. The incidence appears to be stable [18].  
MM is considered to be very sensitive to cytotoxic drugs. However, no cura-
tive treatment approach for this disease exists yet. At diagnosis smouldering 
(asymptomatic) and active (symptomatic) disease can be distinguished. Fur-
ther, the symptomatic disease is classified according to stages following the 
Durie-Salmon staging system (based upon factors correlating with tumour 
cell mass) or the International Staging System (ISS) which incorporates data 
on the levels of serum beta-2 microglobulin (B2M) and serum albumin alone 
to divide disease burden into three stages with prognostic significance. Both 
staging systems have three different levels (stage I-III) and Durie-Salmon 
uses the letters A (normal renal function; serum creatinine level <2.0 
mg/dL) and B (serum creatinine level ≥2.0 mg/dL) for sub-classification 
within the different stages, whereas ISS has the following classification:  
 Stage I — B2M <3.5 mg/L and serum albumin ≥3.5 g/dL  
 Stage II — neither stage I nor stage III  
 Stage III — B2M ≥5.5 mg/L 
The median overall survival for patients with ISS stages I, II, and III are 62, 
44, and 29 months, respectively [19, 20]. 
Binet staging or  
Rai classification 
Multiple Myeloma or 
plasmacytoma an 
incurable disease 
incidence in 2007:  
2.5 per 100,000 
Durie-Salmon staging or 
International Staging 
System (ISS) 
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5 Current treatment 
Indolent Non-Hodgkin’s lymphomas (NHL) 
While indolent NHL is responsive to radiation therapy and chemotherapy, a 
continuous rate of relapse is usually seen in advanced stages. Patients, how-
ever, can often be retreated with considerable success as long as the disease 
histology remains low grade. Patients who present with or convert to aggres-
sive forms of NHL may have sustained complete remissions with combina-
tion chemotherapy regimens or aggressive consolidation with marrow or 
stem cell support [10].  
The most common subtypes of indolent (slow growing) B-cell NHL include 
chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), 
follicular lymphoma and Marginal Zone lymphoma. Different therapeutic 
approaches exist in the treatment of these types of lymphoma and the fol-
lowing substances are used in different chemotherapy regimes:  
- Fludarabine 
- Chlorambucil 
- Cyclophosphamide 
- Vincristine 
- Mitoxantrone 
- Rituximab 
Chronic Lymphocytic Leukaemia (CLL) 
CLL is an extremely heterogeneous disease and not all patients require 
treatment at the time of diagnosis. Therapy is indicated for patients with 
advanced stage disease, high tumour burden, severe disease-related "B" 
symptoms, or repeated infections. 
Among patients with newly diagnosed early stage asymptomatic CLL, ob-
servation is recommended rather than immediate treatment  
Prior to the initiation of active therapy for patients with symptomatic dis-
ease, patients with CLL should undergo a pre-treatment evaluation to de-
termine the extent of disease, patient performance status, and assessment of 
co-morbidities that are likely to have an impact on treatment options.  
For patients with localized (stage I) SLL, treatment with involved-field ra-
diation therapy is recommended alone rather than systemic chemotherapy. 
Patients with stage II or more advanced SLL are treated with chemotherapy 
regimens used for symptomatic CLL. There is no agreed upon standard 
treatment regimen for symptomatic CLL or advanced SLL. There are sev-
eral initial treatment options for patients with symptomatic CLL or ad-
vanced SLL. Treatment options include purine analogs (e.g., fludarabine, 
pentostatin), alkylating agents (e.g., chlorambucil, bendamustine), mono-
clonal antibodies (e.g., rituximab, alemtuzumab), or combinations of these 
agents. Most have not been directly compared. The use of fludarabine-based 
regimes is suggested for most patients. While overall survival rates with the 
different available regimens are similar, they differ in their rates of complete 
remission (CR), time to progression, and associated toxicities. A choice be-
tween these therapies is made based upon patient characteristics and goals 
different therapeutic 
approaches for indolent 
NHL 
fludarabine-based 
regime for most 
patients 
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of therapy. Median overall survival with each of these regimens is approxi-
mately five years.  
The National Cancer Institute Working Group (NCI/WG) and the Interna-
tional Workshop Group on CLL (IWCLL) have developed joint formal cri-
teria for evaluating disease response. The goals and duration of therapy for 
CLL are poorly defined, and there is no evidence that intensification or 
maintenance therapy is of benefit [15, 21]. 
Multiple Myeloma (MM) 
The initial therapy of patients with symptomatic myeloma varies depending 
on whether patients are eligible for autologous hematopoietic cell transplan-
tation (AHCT). If a patient is not a candidate for AHCT, the only treatment 
option is chemotherapy alone. The present choices for induction therapy for 
transplant candidates include bortezomib-, lenalidomide- or thalidomide-
based regimes. All these regimes are also options for non-transplant candi-
dates. Alkylating agents compromise stem cell reserve, and thus are options 
only for non-transplant candidates: Melphalan and prednisone has been 
standard treatment for MM since 1960. The addition of bortezomib or tha-
lidomide is recommended by the NCCN myeloma panel since studies re-
ported superior responses compared to melphalan/prednisone alone [19].  
6 Evidence 
A literature search and contact with Mundipharma GmbH Austria about 
further information, as yet unpublished, on bendamustine have revealed 
three phase III trials for indolent NHL: two full publications, and one ASH 
meeting abstract; one phase III trial for CLL; and one phase III clinical trial 
for MM. In addition, six phase II trials of bendamustine in indolent NHL 
have been published, in addition to one phase II trial in CLL.  No full pub-
lication of phase II trials in MM was identified. 
For indolent NHL, one trial compared bendamustine in combination with 
vincristine and prednisone (BOP) to cyclophosphamide with vincristine and 
prednisone (COP) in patients with advanced indolent non-Hodgkin’s lym-
phoma and mantle cell lymphoma [22].  
Kahl et al. investigated bendamustine monotherapy in patients with rituxi-
mab-refractory, indolent B-cell NHL in a single arm clinical trial [23].  
The third clinical phase III trial was presented by Rummel et al. in 2009 at 
the Annual Meeting of the American Society in Hematology (ASH) [24] and 
compared bendamustine plus rituximab to CHOP plus rituximab as first-
line treatment in patients with advanced follicular, indolent, and mantle cell 
lymphomas. Primary endpoints in these trials were overall response rate 
(ORR), duration of response (DOR), complete remission rate (CR) or pro-
gression-free survival. Overall survival (OS) was only secondary endpoint in 
two trials [22, 24]. 
Six single-arm phase II trials investigated bendamustine either as mono-
therapy in pre-treated low-grade NHL [25] or in rituximab-refractory indo-
lent and transformed NHL [26], bendamustine in combination with vincris-
melphalan and 
prednisone as standard 
treatment 
5 phase III trials for 
NHL, CLL and MM 
3 phase III trials in 
indolent NHL: 
2 full publications, one 
meeting abstract 
 
6 single-arm phase II 
studies  
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tine and prednisolone (BOP) in relapsed and refractory low grade NHL [27] 
or bendamustine plus rituximab in indolent NHL [28-30]. 
In patients with CLL, bendamustine was investigated in a phase III trial 
published by Knauf et al. in 2009 [31]. Bendamustine was compared to 
chlorambucil in 319 patients with previously untreated CLL, primary end-
points were overall response rate and progression-free survival, no comment 
was made on overall survival due to short follow-up. 
Additionally, a fully published single-arm phase II trial of bendamustine 
monotherapy in advanced and refractory CLL is available, primary endpoint 
was complete remission [32]. 
Other phase II trials, such as the combination of bendamustine with rituxi-
mab or the comparison of bendamustine to fludarabine in CLL, are only 
available as meeting abstracts and therefore not further discussed in this re-
view. 
Only one phase III trial of bendamustine in MM was identified in the litera-
ture search. Pönisch et al. investigated bendamustine in combination with 
prednisone compared to melphalan and prednisone in patients with newly 
diagnosed multiple myeloma [33]. Primary endpoint was time-to-treatment 
failure whereas overall survival, on of the secondary endpoints, did not differ 
significantly between treatment groups.  
Further information and detailed results of all mentioned phase III and 
phase II trials is described in sections 6.1. and 6.2 which follow: 
6.1 Efficacy and safety - Phase III studies 
Table 6.1-1. Evidence table of phase III trials in indolent NHL 
Reference  Kahl et al. 2010 [23] Rummel et al., ASH Meeting Ab-
stract 2009 [24] 
Herold et al. 2006 [22] 
Sponsor Research support was provided by 
Cephalon Inc 
Honoraria by Mundipharma Supported by a grant from Ri-
bosepharm GmbH, Germany 
Country USA, Canada Germany Germany 
Design Single-arm, open-label, phase III mul-
ticenter clinical trial 
randomized, phase III multicenter 
clinical trial 
Randomised, open-label, phase III 
multicenter trial 
Participants 
characteristics 
100 pts with rituximab-refractory, 
indolent B-cell NHL 
median age 60 years (range 31-84) 
549 pts (513 randomized pts for the 
final analysis (I=260 pts; C: =253 
pts),  
median patient age: I 64 years,  C 63 
yrs (range 31-83) 
Most patients were in stage IV and 
stage III. Histologies (I vs C: follicular 
55% and 56%, mantle cell 18% and 
19%, and other indolent lymphomas 
27% and 24% 
162 pts (advanced, previously un-
treated indolent NHL and mantle cell
lymphoma 
I 82 pts, mean age 58.1 years 
C 80 pts, mean age 58.4 years 
 
 
 
 
 
one phase III trial in CLL 
one phase III trial in MM 
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Treatments I(ntervention):  
bendamustine 120 mg/m2 on days 1 
+ 2 every 21 days, intravenously in-
fused over 60 to 120 minutes 
 
No control group! 
                              
I(ntervention): Rituximab 375 
mg/m2 (day 1) plus Bendamustine 90
mg/m2 (days 1+2) every 28 days 
C(ontrol): Rituximab 375mg/m2 (day 
1) plus standard CHOP regimen every 
21 days 
(both for a maximum of 6 cycles) 
I(ntervention):  
BOP: bendamustine 60 mg/m2 i.v. 
on days 1-5, vincristine 2mg on day 1 
and prednisone 100 mg/m2 on days 
1-5 i.v. 
(the protocol originally specified 
bendamustine 70 mg/m2, but after 
25 pts had been enrolled, signifi-
cantly higher platelet toxicity was 
observed with the BOP regime com-
pared to COP, and bendamustine 
dose was reduced to 60 mg/m2) 
 
C(ontrol): 
COP: cyclophosphamide 400 mg/m2 
i.v on days 1-5, vincristine 2mg an 
day 1, and prednisone 100 mg/m2 on 
days 1-5 i.v                             
In-/exclusion cri-
teria 
Inclusion: 
≥18 years of age, documented ri-
tuximab-refractory, indolent B-cell 
lymphoma 
WHO performance status ≤2; pa-
tients received 1-3 previous chemo-
therapy regimes 
 
Exclusion: 
Chemotherapy, immunotherapy, ra-
dioimmunotherapy or investiga-
tional therapy within 28 days before 
the start of cycle 1, myeloid growth 
factor treatment within 14 days, con-
current treatment with therapeutic 
doses of systemic steroids within 14 
days, transformed disease, concur-
rent, active malignancy, CNS lym-
phoma, serious infection, expected 
survival <3 months 
first-line therapy, follicular lym-
phoma, indolent and mantle cell 
lymphoma 
Inclusion: 
18-75 years of age, previously un-
treated 
Histological confirmed follicular 
lymphoma, mantle cell lymphoma or 
lymphoplasmoctic lymphoma 
No longer suitable for primary radio-
therapy 
 
Exclusion: 
Previously treated with chemother-
apy or radiotherapy 
WHO performance status >2 
Secondary NHL 
Positive HIV status 
Severe concomitant disease 
Chronic airway disease 
Non-lymphoma related renal or liver 
insufficiency 
Follow-up median follow-up: 11.8 months median observation time was 32 
months 
5 years (median follow up 44 
months) 
Outcomes Primary: overall response rate 
(ORR), duration of response (DOR) 
 
Secondary: safety, progression-free 
survival 
Primary: median progression-free 
survival (PFS) 
 
Secondary endpoints: overall survival
(OS), event-free survival (EFS), time 
to next treatment (TTNT), safety 
Primary: complete remission rate 
 
Secondary: time to progression, time 
to treatment failure (event-free sur-
vival), overall survival, toxicities 
Key results  
 
Primary:  
ORR: 75% (95% CI: 65-83%)  
median DOR: 9.2 months (95% CI: 
7.1 – 10.8 months) 
 
Secondary: 
Median progression-free survival: 9.3 
months (95% CI: 8.1 – 11.9 months) 
Primary:  
median PFS: I 54.8 months vs. C 34.8 
months, p=0.0002, HR = 0.577 
(95%CI 0.429 to 0.768) 
 
Secondary: 
EFS: I 54 months vs. C 31 months,  
p=0.0002, HR = 0.601, 95% CI 0.452 
to 0.785 
OS did not differ between both 
groups at time of analysis (after me-
dian observation time of 32 months)
Primary: complete remission rate: I 
22%  vs. C 20%, p=0.812 
 
Secondary: 
Median time to progression: I 84 
months  vs. C 28 months, p=0.0369 
Time to treatment failure (respond-
ers only): I 27 months vs. C 21 
months, p= 0.05 
Median survival time: I 76 months  
vs. C 54 months, p=0.2 
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Adverse effects 27 patients discontinued treatment 
early due to adverse events, 24 pts 
had dose reductions because of ad-
verse events (neutropenia, thrombo-
cytopenia were most common) 
Grade 3:  neutropenia 38%, throm-
bocytopenia 19%, infections 15% , 
fatigue 12% 
Grade 4:  neutropenia 23%,, throm-
bocytopenia 6%, infections 6% , fa-
tigue 2% 
Overall Grade 3/4: in 61% of patients
Secondary malignancies in 2 pts 
2 episodes of tumor lysis syndrome 
Hematologic toxicities:  
neutropenia grade 3/4: I 10.7% vs. C 
46.5% 
leukocytopenia grade 3/4: I 12.1% vs. 
C 38.2% 
Infectious complications: I 95 pts vs. 
C 121 pts 
deaths: I 34 pts vs. C 33 pts 
Most common and most severe tox-
icities included leucopenia, thrombo-
cytopenia, decreased haemoglobin, 
nausea and vomiting, fever, alopecia 
and infection 
Leucopenia grade 3/4: I 19% vs. C 
34%  
Alopecia grade 3/4: I 32%  vs. C 84% 
Thrombocytopenia more frequent in 
BOP 
treatment related deaths: I 2 pts vs. 
C 0 pts  
secondary neoplasias: I 4 pts vs. C 2 
pts 
Commentary Overall survival was not an endpoint 
of the study 
Overall survival was not primary 
endpoint of the study 
Only meeting abstract, no full publi-
cation available; 
 
No statistically significant difference 
in treatment arms for primary end-
point 
Overall survival was not primary 
endpoint, no difference in overall 
survival 
pts – patients; CI – confidence interval; I – intervention ; C – control ; HR – hazard 
ratio ;  
In these three phase III trials bendamustine was investigated overall in 442 
patients. Due to different study designs (randomized controlled trial vs. sin-
gle-arm trial), patient characteristics (previously untreated NHL vs. rituxi-
mab-refractory NHL) and treatment options (bendamustine monotherapy 
vs. bendamustine combination with rituximab), these trials can not be com-
pared to each other. In addition, bendamustine was administered in three 
different doses ranging from 60 mg/m2 to 120 mg/m2. Overall survival was 
either not considered as an endpoint in the trial or analysed as a secondary 
endpoint. No difference between treatment arms at time of analysis was 
shown.  
Herold et al. [22] compared bendamustine combination therapy to the COP 
regime which has been considered as standard treatment for patients with 
indolent NHL but did not detect a significant difference in complete remis-
sion rate (primary endpoint) between both treatment groups. Although a 
benefit for the bendamustine combination (BOP) over COP was shown in 
some secondary endpoints, its role in these patients remains unclear. There 
is no other equal clinical trial comparing this bendamustine-based regime 
versus COP available.  
Rummel et al. [24] investigated bendamustine in combination with rituxi-
mab versus CHOP plus rituximab in previously untreated patients (first-line 
treatment) and showed the final results at the ASH Annual Meeting in 2009. 
The median progression-free survival (primary endpoint) was significantly 
longer in the bendamustine group (54.8 months versus 34.8 months in con-
trol group, p=0.0002). This is the only phase III trial of bendamustine in 
combination with rituximab as first-line treatment in patients with indolent 
NHL. The full final publication remains to be seen. 
The third phase III trial [23] was as single-arm study investigating benda-
mustine monotherapy in rituximab-refractory indolent NHL. An overall re-
sponse rate of 75%  (65-83%, 95%CI) was observed which is comparable 
with the result of a previous phase II trial [26] by Friedberg et al. (ORR = 
77%). This phase III trial was one of the relevant studies considered by the 
FDA for the approval of bendamustine monotherapy in rituximab-refractory 
indolent NHL in the USA in 2008.  
442 patients overall in 
bendamustine group 
no significant difference 
in primary endpoint 
meeting abstract 
PFS significantly longer 
in bendamustine group 
single-arm phase III 
study 
overall response rate of 
75%  
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The most common adverse events in these trials were grade 3 or 4 neutro-
penia, thrombocytopenia, anaemia, infection, nausea and other non-
haematological adverse events as described in table 6.1-1. 
 
Table 6.1-2. Evidence table of phase III trial in Chronic Lymphocytic Leukaemia (CLL) 
Reference  Knauf et al. 2009 [31] 
Sponsor Supported by grants from Ribosepharm GmbH Germany and Mundipharma International 
Country Multicenter (45 centers in Austria, Bulgaria, France, Germany, Italy, Spain, Sweden and UK) 
Design randomized, open-label, parallel-group, phase III multicenter trial 
Participants characteristics 319 previously untreated patients with advanced (Binet stage B or C) CLL 
Intervention: 162 pts, mean age 63 years, Binet stage B: 116 pts and stage C 46 pts 
Control: 157 pts, mean age 63.6 years, Binet stage B: 111 pts and stage C 46 pts 
Comparable WHO performance status in both groups 
Treatments I(ntervention):  
Bendamustine at a dose of 100 mg/m2/d on days 1 and 2 every 4 weeks as intravenous infusion 
over 30 min 
 
C(ontrol): 
Chlorambucil orally at a dose of 0.8 mg/kg on days 1 and 15 every 4 weeks                                 
In-/exclusion criteria Inclusion: 
Previously untreated patients, Age up to 75 years, Binet stage B or C, WHO performance 
status of 0 to 2, Life expectancy of at least 3 months 
 
Exclusion: 
Patients with second malignancy, Patients with manifest immune haemolysis or thrombocy-
topenia, Richter’s syndrome, Hepatic or renal dysfunction, Mental disorders, HIV infection,  
Major surgery within 30 days before start of trial 
Follow-up Median observation time 35 months (range 1 to 68) 
Outcomes Primary: overall response rate, progression-free survival 
 
Secondary: time to progression, duration of remission, overall survival, safety 
Key results  
 
Primary:  
overall response rate (CR or PR): I 68%  vs. C 31%, p<0.0001 
median progression-free survival: I 21.6 months vs. C 8.3 months, p<0.0001 
 
Secondary:  
median duration of response: I 21.8 months vs. C 8.0 months, p<0.0001  
time to progression not reported; no difference in overall survival at time of analysis 
Adverse effects Withdrawal due to toxicities: I 18 pts  vs. C 5 pts 
AEs grade 3/4: 
Neutropenia/granulocytopenia: I 23% vs. C 10.6% 
Leukopenia: I 14.3% vs. C 1.3% 
Thrombocyotopenia: I 11.8% vs. C 7.9% 
Infections: I 8% vs. C 3% 
More adverse events (all grades)  in bendamustine group: hypersensitivity reactions, hemato-
logic events (neutropenia, thrombocytopenia, anemia, leukopenia) and GI events (nausea, 
vomiting), severe infections, two reports on tumor lysis syndrome in bendamustine group 
Commentary ITT analysis (6 patients randomly assigned to chlormabucil and one to bendamustine were not 
treated), safety population 312 pts treated 
Overall survival was not primary endpoint, no difference in overall survival after median ob-
servation time of 35 months 
Adverse events in bendamustine group more frequent although manageable 
pts – patients; I – intervention ; C – control ; CR – complete response ; PR – partial 
response ; AEs – adverse events ; ITT – intention to treat ;  
 
mainly haematological 
adverse events 
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This phase III randomized clinical trial compared bendamustine to 
chlorambucil in a total of 319 previously untreated patients with advanced 
(Binet stage B or C) CLL. A complete response was achieved in 31% ben-
damustine-treated patients and in 2% of chlorambucil-treated patients, the 
median progression-free survival was 21.6 months in the bendamustine 
group and 8.3 months in the chlorambucil group (p< 0.0001) but no signifi-
cant difference in overall survival has yet been observed.  
18 patients from the bendamustine and 5 from the chlorambucil group were 
withdrawn from the study due to unacceptable toxicity. In general, more 
grade 3/4 adverse events were observed in bendamustine-treated patients, 
especially neutropenia and leukopenia, hypersensitivity and infections. In 
addition, two reports on tumor lysis (although not fatal) were observed in 
the bendamustine group, none in the control group.  
No other phase III clinical trial of bendamustine in patients with CLL has 
been published so far.  
 
Table 6.1-3. Evidence table of phase III trial in Multiple Myeloma (MM) 
Reference  Po¨nisch et al. 2006 [33] 
Sponsor East German Study Group of Hematology and Oncolgy (OSHO) – sponsored by Mundipharma 
(Ribosepharma GmbH Germany) 
Country Germany 
Design Prospective, open-label, randomized, multicenter, phase III trial 
Participants characteristics 131 pts (previously untreated patients) 
I: 68 pts; median age 62 yrs (range 38 – 76 years); stage II with progression MM: 7 pts; stage 
III MM: 61 pts 
C: 63 pts; median age 62 (range 42 – 80 years); stage II with progression MM: 4 pts; stage III 
MM: 59 pts 
Treatments I(ntervention):  
Prednisone (60 mg/m2 intravenously or orally) on days 1-4 in combination with bendamustine 
(150 mg/m2 in 500ml NaCl 0.9% as intravenous infusion over 30 min) on days 1 and 2 
 
C(ontrol): 
Prednisone (60 mg/m2 intravenously or orally) on days 1-4 in combination with melphalan (15 
mg/m2 in 100 ml NaCl 0.9% intravenously over 30 min) on day 1 
 
Treatment was administered every 28 days until maximum remission or disease progression 
was observed. Patients had to receive at least two cycles of chemotherapy for efficacy to be 
evaluated.                                 
In-/exclusion criteria Inclusion: 
Stage II with progression or stage III MM (Durie & Salmon System), Quantitatively measur-
able myeloma proteins, Leukocyte count ≥2,000/l, Platelet count ≥50,000/l, Karnofsky per-
formance status of ≥60%, Life expectancy of  ≥3 months, Nor prior chemotherapy or ra-
diotherapy 
 
Exclusion: 
Nonsecretory and local plasmacytoma, HIV or Hbs-AG positivity or active hepatitis, Secondary 
malignancy, Serious concomitant diseases 
Follow-up until maximum remission or disease progression 
Outcomes Primary: time to treatment failure (TTF) 
Secondary: survival, remission rate, toxicity, quality of life 
 
 
 
bendamustine compared 
to chlorambucil 
PFS significantly longer 
in bendamustine group 
more grade 3/4 AEs in 
bendamustine group 
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Key results  
 
Primary:  
TTF: I 14 months vs. C 10 months, p<0.02 
 
Secondary:  
median overall survival: I 32 months vs. C  33 months, NS 
Overall remission rate (CR and PR): I 75%  vs. C 70%, NS 
CR: I 32% vs. C 13%, p=0.007 
PR: I 43% vs. C 57% , NS 
QoL: I superior in global status of health and emotional functioning at 4 and 6 months 
Adverse effects Grade 3/4: 
nausea and vomiting: I 12%  vs. C 0%  
anaemia: I 24% vs. C 24%  
leukocytopenia: I 40% vs. C 31% 
thrombocytopenia: I 10% vs. C 15% 
Commentary Overall survival was not primary endpoint, no difference in overall survival 
No ITT analysis (136 patients enrolled, 131 pts evaluated for analysis 
Crossover to alternative treatment in case of progression was allowed, but no crossover analy-
sis  
MM - multiple myeloma; TTF - time to treatment failure, CR - complete remission, 
PR - partial remission, pts - patients, NS - not significant, ITT -intention to 
treat; I – intervention ; C – control ; QoL – quality of life;  
There is only one randomized phase III clinical trial of bendamustine in pa-
tients with multiple myeloma published. Pönisch et al. compared benda-
mustine with prednisone to the standard therapy of melphalan with predni-
sone in patients with previously untreated MM (first-line therapy).  
Of the 136 enrolled patients, only 131 patients were analyzed for the primary 
endpoint ‘time to treatment failure (TTF)’, which was 14 months in the 
bendamustine group and 10 months in the control group (p<0.02). They did 
not observe any differences in the median overall survival. The study design 
allowed crossover to the alternative treatment in the case of disease progres-
sion during therapy or within the 3-month therapy-free interval: 9 patients 
of the bendamustine group and 13 patients of the melphalan group changed 
the treatment, but no cross-over analysis was performed.  
Although haematological toxicities were comparable in both arms, more pa-
tients in the bendamustine group required a dose reduction due to adverse 
events such as leukocytopenia and thrombocytopenia.  Grade 3/4 nausea and 
vomiting was observed in 12% of patients in the bendamustine group, but in 
no case in the control group. 
Although the study assessed quality of life as secondary endpoint, only a 
small proportion of questionnaires were available for analysis (23 out of 68 
in bendamustine group, 19 out of 63 in melphalan group).  A positive effect 
was seen 4 months after treatment and remained so beyond 6 months, but 
nothing was mentioned about the effect at a later point of time. 
 
 
bendamustine with 
prednisone compared to 
melphalan with 
prednisone 
no difference in median 
overall survival 
comparable toxicities in 
both arms 
limited results for 
quality of life 
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6.2 Efficacy and safety - further studies 
Indolent NHL 
In addition to the three phase III studies of bendamustine in patients with 
indolent NHL, we identified six non-randomized phase II clinical trials in-
vestigating bendamustine either in monotherapy or in different combination 
therapy regimes for patients with pre-treated relapsed or refractory indolent 
(low-grade) NHL.  
Bendamustine Monotherapy 
- Bremer et al. 2002 [25] conducted a phase II single arm study of 
bendamustine as salvage therapy in 102 pre-treated low-grade NHL 
patients ( with different histological subtypes). The overall remis-
sion rate was 76.5% (78/102 patients), the median overall survival 
was 29 months. Serious non-haematological side effects (≥grade 3 
or 4) were less frequent than haematological toxicity such as leuko-
penia (25%), thrombocytopenia (more than 20%) and anaemia 
(about 30%). 
- Friedberg et al 2008 [26] conducted a phase II multicenter study to 
evaluate bendamustine monotherapy in patients with B-cell NHL 
refractory to rituximab. 76 patients with a median age of 63 years 
were treated. The overall response rate was 77%, the median pro-
gression-free survival was 8.3 months (95% CI, 6.6 to 10.9),, The 
observed adverse events were grade 3 or 4 neutropenia (54%), ane-
mia (12%) and thrombocytopenia (25%) and non-hematological 
adverse events like nausea, vomiting and fatigue.  
Bendamustine in combination with other cytotoxic agents or rituximab 
- Kath et al. 2000 [27] conducted an open phase II study of benda-
mustine in combination with vincristine and prednisolone in pa-
tients with relapsed and refractory low grade NHL. 22 patients with 
a median age of 61.5 years were treated with bendamustine as sal-
vage therapy. Objective remission was achieved in 86% (19/22 pa-
tients), haematological adverse events were the most frequent ones 
and a decline of the CD4/CD8 (ratio was observed in more than 
50% of patients. 
- Rummel et al 2005 [29] conducted an open label phase II multicen-
ter trial of bendamustine in combination with rituximab in patients 
with mantle cell or low grade NHL in first to third relapse or re-
fractory to previous treatment. 63 patients with a median age of 64 
years were treated. The median progression-free survival was 24 
months (range 5 to 44+ months) for all patients. Leukocytopenia 
was the major toxicity. 
- Weide et al. 2007 [28] conducted a multicenter phase II study of 
bendamustine in combination with mitoxantrone and rituximab in 
patients with stage III/IV relapsed or refractory indolent NHL and 
mantle cell lymphoma with or without prior rituximab containing 
treatment. 57 patients were treated with a median age of 66 years. 
The overall response rate was 89% and the estimated progression-
free survival was 19 months. The most frequent adverse events were 
additionally six 
phase II trials 
bendamustine as 
salvage therapy 
median PFS 8.3 months 
 
combination with 
vincristine and 
prednisolone 
combination with 
rituximab 
median PFS 24 months 
combination with 
mitoxantrone and 
rituximab 
overall response rate 
89% 
 LBI-HTA | 2010 17 
grade 3 or 4 leukocytopenia (78%), granulocytopenia (46%), 
thrombocytopenia (16%) and anaemia (10%). 
- Robinson et al. 2008 [30] conducted a multicenter, open-label, sin-
gle-arm phase II study of bendamustine with rituximab in patients 
with relapsed, indolent B-cell or mantle cell lymphoma. 66 patients 
with a median age of 60 years were treated. The overall response 
rate was 92% and the median progression-free survival was 23 
months (95% CI, 20 to 26 months). The most common adverse 
events were leukopenia (94%), neutropenia (79%), anaemia (77%), 
thrombocytopenia (62%), nausea (70%) and infection (64%).  
At present, other phase II studies of bendamustine in patients with indolent 
NHL are only available as meeting abstracts. They will be considered for 
evidence as soon as full publications are available.  
Chronic Lymphocytic Leukaemia 
In addition to the phase III study mentioned above (Knauf et al. 2009), one 
fully published small phase II trial investigating bendamustine monother-
apy in patients with advanced, refractory or relapsed CLL was identified. 
The single-centre phase II study determined the activity and toxicity of 
monotherapy with bendamustine in 23 patients (median age 62 years) with 
previously treated (n=10) and untreated (n=13) CLL [32]. A complete or 
partial remission was achieved in 15/20 patients (75%), including six pa-
tients with complete response. Median overall survival was calculated as 13.6 
months. WHO grade 3/4 leukocytopenia was very frequent and resulted in 
treatment-related deaths in 3/23 patients.  A decline of the lymphocyte 
CD4/CD8 ratio which could lead to additional immunosuppression with 
subsequent infectious complications was observed in all patients.  
As above, other phase II studies of bendamustine in patients with CLL are 
only available as meeting abstracts. They will be considered for evidence as 
soon as full publications are available. 
Multiple Myeloma 
No published phase II clinical trial was identified by the literature search. 
Other investigations (e.g. phase I trials, clinical observations) in patients 
with recurrent, advanced or refractory relapsed multiple myeloma are only 
available as meeting abstract. Two phase II trials in patients with MM are 
currently ongoing, results are expected for 2012 (see chapter 8 – ongoing re-
search). 
combination with 
rituximab 
median PFS 23 months 
one additional phase II 
trial in CLL 
median OS 13.6 months 
no other fully published 
clinical trial in MM 
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7 Estimated costs 
One vial Ribomustin® (Bendamustine) 25mg costs € 44,- whereas one vial 
Ribomustin 100mg costs € 267,-. The costs of Levact® (bendamustine) which 
is currently undergoing regulatory review in 12 countries across Europe are 
not known. [34]  
 
Assuming an average body surface of 1.7 m2 for NHL, CLL and MM pa-
tients and considering the recommended dosages, the costs per cycle for 
these indications would be 
 
- € 1,335,- (Bendamustine in combination therapy; 60 mg/m2, Days 
1-5); € 1,068,- (Bendamustine monotherapy; 120 mg/m2, Days 1+2) 
in NHL treatment 
- € 622,- to € 798,- (€ 1,068,-, if only 100mg vials of bendamustine are 
used) - (Bendamustine 70 - 100 mg/m2, Days 1+2) in CLL treat-
ment 
- € 1,068,- to € 1,244,- (Bendamustine 120 - 150 mg/m2, Days 1+2) in 
MM treatment  
 
Since Bendamustine is an old drug belonging to the group of alkylating 
agents, treatment costs are low compared to newer targeted anticancer 
therapies like monoclonal antibodies. Nevertheless the costs for Levact®, 
Mundipharma’s new bendamustine product, have to be awaited.  
8 Ongoing research 
According to ClinicalTrials.gov (www.clinicaltrials.gov), a registry of feder-
ally and privately supported clinical trials conducted in the United States 
and around the world and a service of the U.S. National Institutes of Health, 
several clinical trials of bendamustine are currently being conducted in pa-
tients with different cancer diseases. 
Indolent NHL 
Four phase III trials are investigating the efficacy of bendamustine in pa-
tients with indolent NHL. The trials either use bendamustine monotherapy 
or bendamustine in combination with different antibodies: 
 
- One study (NCT00139841), sponsored by Cepahlon, was completed 
only recently in May 2010. It is a multicenter phase III non-
randomized study which investigated the safety and efficacy of Tre-
anda® (Bendamustine HCl) in patients with indolent Non-
Hodgkin's Lymphoma (NHL) who are refractory to rituximab. The 
study started in 2005; primary endpoint was overall response rate. 
The results have not been published yet. 
 
- An open-label, randomized, parallel-group phase III study 
(NCT00877006), again sponsored by Cephalon, is investigating 
bendamustine hydrochloride and rituximab (BR) compared to ri-
costs per cycle for NHL, 
CLL and MM range from 
€ 622,- to € 1.335,- 
up to 6 cycles 
costs for LEVACT® not 
known yet 
four phase III studies in 
indolent NHL are 
ongoing 
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tuximab, cyclophosphamide, vincristine, and prednisone (R-CVP) 
or to rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) in the first-line treatment of patients with 
advanced indolent Non-Hodgkin's Lymphoma (NHL) or Mantle 
Cell Lymphoma (MCL). The study started in 2009 and will be 
completed in 2017; primary endpoint is complete response rate. 
 
- One study (NCT01077518), sponsored by GlaxoSmithKline and 
starting June 2010 will evaluate the safety and efficacy of ofatumu-
mab (Arzerra®) and bendamustine combination therapy in patients 
with indolent B-cell NHL that did not respond to rituximab or a ri-
tuximab-containing regimen during or within 6 months of the last 
rituximab treatment. The study will last until 2022. Ofatumumab is 
a monoclonal antibody targeting CD20.  
 
- One study (NCT01059630), sponsored by Genentech, is an open-
label, randomized phase III trial investigating the efficacy and 
safety of GA101 combined with bendamustine compared to benda-
mustine alone in patients with rituximab-refractory, indolent Non-
Hodgkin's lymphoma (NHL). RO5072759 (GA101) is the first hu-
manized and glycoengineered monoclonal anti-CD20 antibody. The 
study lasts until 2015. 
CLL 
Bendamustine in patients with CLL is currently being investigated in one 
phase IV and one phase III clinical trial: 
 
- The phase IV study (NCT01056510), sponsored by Hoffmann La-
Roche, is a randomized study to assess the effect on response rate of 
MabThera (Rituximab) added to a standard chemotherapy, benda-
mustine or chlorambucil, in patients with Chronic Lymphocytic 
Leukaemia. The study will be completed in 2013. 
 
- A randomized, open-label phase III clinical trial (NCT00769522), 
by the German CLL Study Group, is investigating combined im-
munochemotherapy with fludarabine, cyclophosphamide and ri-
tuximab (FCR) versus bendamustine and rituximab (BR) in pa-
tients with previously untreated Chronic Lymphocytic Leukaemia. 
The primary outcome is the progression-free survival rate after 24 
months. The study will be completed in 2018. 
Several ongoing phase II trials in patients with NHL and CLL are listed on 
the ClinicalTrials website. These trials investigate bendamustine in combi-
nation with various other anticancer drugs (e.g. bortezomib, alemtuzumab, 
ofatumumab, rituximab, mitoxantrone) and in different stages or therapy 
lines of NHL and CLL. 
Multiple Myeloma 
There is no phase III clinical trial of bendamustine in multiple myeloma 
listed at clinicaltrials.gov, but phase II and phase I/II studies are currently 
investigating bendamustine either in combination with bortezomib or le-
nalidomide in patients with MM. The phase II trials are listed here: 
one phase III and one 
phase IV study in CLL 
are ongoing 
no phase III, but two 
phase II in MM are 
ongoing 
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- A non-randomized, phase II trial (NCT01045681) by Intergroupe 
Francophone du Myelome is investigating bendamustine, borte-
zomib (Velcade®) and Dexamethasone (BVD) in the treatment of 
elderly patients (>= 65 Years) with multiple myeloma in 1st re-
lapse or refractory to first-line therapy. The primary outcome is 
overall response rate. The study will be completed in 2012. 
- A phase II study (NCT01056276) by Sarah Cannon Research Insti-
tute and sponsored by Cephalon and Millenium Pharmaceuticals 
Inc. is investigating bendamustine, bortezomib and dexamethasone 
(BBD) in the first-line treatment of patients with Multiple Mye-
loma who are not candidates for high dose chemotherapy. The trial 
lasts until 2012. 
Other Cancer Types 
Bendamustine is currently being investigated in several other indications in 
oncology within phase I/II or phase II clinical trials, e.g. ovarian cancer, 
small cell lung cancer (SCLC), acute myeloid leukaemia (AML), breast can-
cer and soft tissue sarcoma.  
 
9 Commentary 
Due to disagreement among several EU member states, the EMA was con-
tacted by the German medicines regulatory agency within the decentralised 
approval procedure for bendamustine (Levact®). EMA’s CHMP concluded 
in March 2010 that marketing authorisation for bendamustine can be 
granted in Germany and 12 other member states of the EU for three indica-
tions (CLL, NHL and MM). The FDA, on the other hand, approved benda-
mustine (Treanda®) only for CLL and NHL in 2008.  
Although drug costs of bendamustine are considered to be low compared to 
other especially newer targeted cancer therapies, its use in patients with in-
dolent NHL, CLL and MM should be evidence based. The benefits and risks 
of bendamustine-based therapy have to be balanced carefully and have to be 
assessed out of a patients’ perspective. The current evidence and recommen-
dations for bendamustine in these indications, based on the identified trials 
mentioned above, are summarized subsequently. 
Bendamustine in Patients with Indolent Non-Hodgkin’s 
lymphomas (NHL) 
Although several phase III as well as phase II studies which assessed ben-
damustine for the treatment of NHL were found, the heterogeneity of NHL 
and the differences in treatment regimens (i.e. first- vs. second-line therapy, 
differing dosing regimens, differing combinations) make it difficult to con-
clusively judge the potential clinical benefit associated with bendamustine 
therapy. Despite data indicating improvements in progression-free survival, 
overall response rate or overall remission rate, to date no trial has demon-
strated increases in overall survival or quality of life (QoL). 
bendamustine for 
ovarian cancer, SCLC, 
AML / MDS, breast 
cancer and soft tissue 
sarcoma 
evidence-based use and 
balancing benefits and 
risks 
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The NCCN guidelines ‘Non-Hodgkin’s Lymphomas’ include bendamustine 
with or without rituximab as an option for second-line therapy for patients 
with relapsed or refractory NHL. This recommendation is only based on 
low-level evidence (2B recommendation) because only limited data are 
available for this indication [35]. 
Due to current reported data, its reasonable safety profile and its low costs, 
bendamustine can be seen as an additional therapeutic option for some pa-
tients with indolent NHL but further trials are needed. The results of these 
trials will help to better identify the role of bendamustine among treatment 
options for indolent NHL. In addition, the optimal dose and schedule have 
to be defined and toxicities (mainly grade 3/4 haematological adverse 
events) have to be monitored when bendamustine is used.  
Bendamustine in Patients with Chronic Lymphocytic Leu-
kaemia (CLL) 
To date one phase III randomized clinical trial (Knauf et al. 2009) compar-
ing bendamustine with chlorambucil for first-line therapy in patients with 
CLL is published. Although the primary endpoints overall response rate 
(68% versus 31%, p<0.0001) and median progression-free survival (PFS = 
21.6 months versus 8.3 months, p<0.0001) were favoured in the benda-
mustine group, no difference in overall survival was observed between both 
arms at time of analysis (after median observation time of 35 months). How-
ever, the approval of bendamustine for CLL patients was based on this 
phase III trial. Adverse events especially hematologic toxicity and infections 
were more frequent in the bendamustine group. Since fludarabine-based re-
gimes are considered as standard choice for most patients with CLL, trials 
comparing bendamustine with fludarabine are necessary to further investi-
gate the role of bendamustine in patients with previously untreated CLL. 
Regarding other treatment regimes, the role of bendamustine in combina-
tion with rituximab for first-line therapy or bendamustine-based treatment 
for patients with relapsed or refractory CLL remains still unclear, since 
there are no randomized clinical trials available. 
The CHMP recommended granting marketing authorisation within EU 
member states for “bendamustine for CLL in patients for whom treatment 
with fludarabine is not appropriate”.  In addition, although bendamustine is 
approved by FDA for CLL patients and the NCCN guidelines ‘Non-
Hodgkin’s Lymphomas’ include bendamustine as single-agent for first-line 
therapy and as single-agent or in combination with rituximab for second-
line therapy, these recommendations are based on limited evidence [35]. Ef-
ficacy of bendamustine compared to other therapies than chlorambucil has 
not yet been established in randomized clinical trials and full publications 
on efficacy and safety are still required. 
In summary, the use of bendamustine for first-line therapy in patients with 
CLL is currently based on one published randomized phase III trial and re-
sults of other clinical trials have to been seen to evaluate its role in second-
line CLL therapy. Despite preliminary evidence based on meeting abstracts 
or published non-randomized trials, bendamustine can be seen as salvage 
therapy for patients with CLL. The observation of hematologic toxicity and 
a decline in the CD4/8 ratio (possibly responsible for higher infection rate) 
in bendamustine treated patients which require dose reduction, end of ben-
damustine treatment or additional therapy should led to carefully balancing 
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the risks and benefits of bendamustine therapy. Further trials investigating 
bendamustine-based treatments are necessary to clearly define its role in pa-
tients with CLL. 
Bendamustine in Patients with Multiple Myeloma (MM) 
Evidence of bendamustine in patients with MM is still limited. Only one 
study (RCT) of bendamustine in patients with multiple myeloma has been 
published. This phase III clinical trial compared bendamustine to a melpha-
lan-based standard treatment in 131 patients newly diagnosed MM, 68 pa-
tients were treated with the bendamustine-based regime (see table 6.1-3). Al-
though the primary endpoint ‘time to treatment failure’ was significantly 
longer in the bendamustine group, no difference in overall survival was ob-
served. The toxicities in the two arms were comparable. In summary, the 
trial did not show a clear advantage of bendamustine over melphalan-based 
standard treatment. No other randomized trials are available. The two ongo-
ing phase II trials of bendamustine in patients with MM are non random-
ized, single-arm studies and investigate a different treatment regime - ben-
damustine in combination with bortezomib. The results of these trials are 
not conclusive with regard to the role of bendamustine compared to stan-
dard treatment for first-line therapy of patients with MM.  
In summary, evidence for bendamustine in patients with MM is limited and 
its value in MM treatment remains unclear. The NCCN ‘Multiple Myeloma’ 
guideline recommends bendamustine as salvage therapy (based on low-level 
evidence, category 2B) [19] and the European Medicines Agency (EMA) in-
dicates bendamustine “for the treatment of multiple myeloma in combina-
tion with prednisone for patients older than 65 years who are not eligible for 
autologous stem cell transplantation and cannot be treated with thalidomide 
or bortezomib” [1]. Bendamustine is not approved by the FDA for the 
treatment of MM. Further trials are needed to demonstrate efficacy of ben-
damustine in patients with MM and to address issues such as overall sur-
vival and quality of life.  
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